Metis Global Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $308K | Sell |
2,452
-640
| -21% | -$80.4K | 0.01% | 655 |
|
|
2025
Q1 | $342K | Buy |
3,092
+544
| +21% | +$60.2K | 0.01% | 645 |
|
|
2024
Q4 | $348K | Buy |
2,548
+104
| +4% | +$14.2K | 0.01% | 642 |
|
|
2024
Q3 | $282K | Buy |
2,444
+203
| +9% | +$23.4K | 0.01% | 682 |
|
|
2024
Q2 | $309K | Buy |
2,241
+30
| +1% | +$4.13K | 0.01% | 650 |
|
|
2024
Q1 | $305K | Sell |
2,211
-19
| -0.9% | -$2.62K | 0.01% | 656 |
|
|
2023
Q4 | $294K | Sell |
2,230
-131
| -6% | -$17.3K | 0.01% | 647 |
|
|
2023
Q3 | $266K | Buy |
2,361
+106
| +5% | +$11.9K | 0.01% | 654 |
|
|
2023
Q2 | $213K | Buy |
2,255
+176
| +8% | +$16.6K | 0.01% | 671 |
|
|
2023
Q1 | $210K | Buy |
+2,079
| New | +$210K | 0.01% | 627 |
|